**Don't have 30 minutes to listen? Find out what our experienced panel think about the future of lateral flow in this easy-to-read PDF guide. Download now.**
Lateral flow tests have been crucial in the global response to the COVID-19 pandemic and will be a major part of the world’s return to normality. But what's next for the technology?
In this live webinar, I asked three experienced commercial leaders about their insights, advice and predictions on the future of this market. Our panel included:
- Leigh Thomas - Senior VP, Director of Global Sales at Abingdon Health
- Angus Urquhart - Sales Director at Katalyst Laboratories
- Robert Miller - President of Drummond Scientific
We discussed where the future opportunity lies for lateral flow, plus how these experts are challenging the technology’s inaccurate reputation and pitching it alongside other point-of-care diagnostic solutions.
If you'd like to learn more about the panel or myself, feel free to get in touch via Nathan.Sharpe@lifesci-cm.com.
You can find more content about our discussion via my profile page. You'll also be able to find a similar podcast I recorded with Jonathan O’Halloran, who is CEO at QuantuMDx, which was about the broader question: What's Next for POC Diagnostics?